Going back to class I: MHC and immunotherapies for childhood cancer

Kellie B. Haworth, Jennifer L. Leddon, Chun Yu Chen, Edwin M. Horwitz, Crystal L. Mackall, Timothy P. Cripe

Research output: Contribution to journalReview article

Abstract

After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.Pediatr Blood Cancer 2015;62:571-576.

Original languageEnglish (US)
Pages (from-to)571-576
Number of pages6
JournalPediatric Blood and Cancer
Volume62
Issue number4
DOIs
StatePublished - Apr 1 2015

Keywords

  • Childhood cancers
  • Immunotherapy
  • MHC Class I

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Going back to class I: MHC and immunotherapies for childhood cancer'. Together they form a unique fingerprint.

  • Cite this

    Haworth, K. B., Leddon, J. L., Chen, C. Y., Horwitz, E. M., Mackall, C. L., & Cripe, T. P. (2015). Going back to class I: MHC and immunotherapies for childhood cancer. Pediatric Blood and Cancer, 62(4), 571-576. https://doi.org/10.1002/pbc.25359